Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim is fully supported by the cited FDA label sections (5.1 and 8.4), including the increased risk in age ≤24 and pediatric patients and the need for close monitoring, particularly during initial treatment and dosage changes.
Category Scores
Accurate Statements
TRINTELLIX (vortioxetine) is associated with an increased risk of suicidal thoughts and behaviors in adolescents and young adults (≤24 years).
Supported by label section 5.1 stating pooled analyses showed incidence of suicidal thoughts/behaviors in antidepressant-treated patients age 24 and younger was greater than placebo.
TRINTELLIX is associated with an increased risk of suicidal thoughts and behaviors in pediatric patients.
Supported by label section 8.4 stating antidepressants such as TRINTELLIX increase the risk of suicidal thoughts and behaviors in pediatric patients.
Patients should be monitored closely, especially during initial treatment and dosage changes.
Supported by label section 5.1 instructing to monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts/behaviors, especially during the initial few months and at times of dosage changes.
Unsupported Statements
Contradictions
Important Omissions
The claim does not mention the label’s additional counseling/monitoring instructions for family/caregivers and consideration of changing the therapeutic regimen (including possibly discontinuing) in cases of persistently worse depression or emergent suicidal thoughts/behaviors.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim accurately reflects label warnings about increased suicidal thoughts/behaviors risk and monitoring priorities; it does not introduce incorrect risk magnitude or contraindications.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of caregiver counseling and regimen-change considerations present in section 5.1.
Suggested Improvement
Include the label’s guidance to counsel family/caregivers to monitor and to consider changing the therapeutic regimen (including possibly discontinuing) for persistently worse depression or emergent suicidal thoughts/behaviors.